Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-03-24 | Bassler Bonnie L (Director) | Sale | 1,240 | 818.00 | 1,014,320 |
| 2023-03-24 | Bassler Bonnie L (Director) | Option Ex | 1,240 | 380.95 | 472,378 |
| 2023-03-23 | Fenimore Christopher R. (SVP Controller) | Sale | 2,192 | 806.47 | 1,767,782 |
| 2023-03-23 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 10,000 | 270.43 | 2,704,300 |
| 2023-03-23 | Yancopoulos George (President and Chief Scientific) | Sale | 3,656 | 804.29 | 2,940,469 |
| 2023-03-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 759.89 | 835,879 |
| 2023-03-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 372.46 | 409,706 |
| 2023-03-01 | Ryan Arthur F (Director) | Sale | 100 | 762.44 | 76,244 |
| 2023-02-22 | Vagelos P Roy (Director) | Option Ex | 42,500 | 270.43 | 11,493,275 |
| 2023-02-07 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 769.04 | 769,040 |
| 2023-02-07 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 372.46 | 372,460 |
| 2023-02-06 | Landry Robert E (EVP Finance CFO) | Sale | 752 | 790.24 | 594,263 |
| 2023-02-06 | Yancopoulos George (President and Chief Scientific) | Sale | 13,189 | 800.08 | 10,552,255 |
| 2023-02-06 | Goldstein Joseph L (Director) | Sale | 3,613 | 800.00 | 2,890,400 |
| 2023-02-06 | Goldstein Joseph L (Director) | Option Ex | 3,613 | 482.68 | 1,743,922 |
| 2023-02-06 | Brown Michael S (Director) | Sale | 3,571 | 797.50 | 2,847,872 |
| 2023-02-06 | Brown Michael S (Director) | Option Ex | 3,071 | 520.01 | 1,596,950 |
| 2023-02-03 | Fenimore Christopher R. (SVP Controller) | Option Ex | 5,000 | 270.43 | 1,352,150 |
| 2023-02-03 | Bassler Bonnie L (Director) | Sale | 1,021 | 779.00 | 795,359 |
| 2023-02-03 | Bassler Bonnie L (Director) | Option Ex | 1,021 | 380.95 | 388,949 |
| 2023-02-03 | Landry Robert E (EVP Finance CFO) | Sale | 739 | 764.50 | 564,965 |
| 2023-02-03 | Landry Robert E (EVP Finance CFO) | Option Ex | 3,000 | 381.92 | 1,145,760 |
| 2023-02-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 752.19 | 827,409 |
| 2023-02-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 372.46 | 409,706 |
| 2023-02-01 | Ryan Arthur F (Director) | Sale | 100 | 757.46 | 75,745 |
| 2023-01-27 | Brown Michael S (Director) | Sale | 1 | 747.00 | 747 |
| 2023-01-27 | Brown Michael S (Director) | Option Ex | 1 | 520.01 | 520 |
| 2022-12-28 | Coles N Anthony (Director) | Sale | 5,758 | 712.52 | 4,102,718 |
| 2022-12-28 | Coles N Anthony (Director) | Option Ex | 5,758 | 428.40 | 2,466,727 |
| 2022-11-23 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Sale | 11,972 | 741.95 | 8,882,637 |
| 2022-11-22 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Option Ex | 50,000 | 378.98 | 18,949,000 |
| 2022-11-15 | Murphy Andrew J (EVP Research) | Sale | 3,720 | 730.70 | 2,718,185 |
| 2022-11-14 | Murphy Andrew J (EVP Research) | Option Ex | 10,000 | 179.13 | 1,791,300 |
| 2022-11-08 | Brown Michael S (Director) | Sale | 4,495 | 758.97 | 3,411,588 |
| 2022-11-08 | Brown Michael S (Director) | Option Ex | 3,995 | 428.40 | 1,711,458 |
| 2022-11-07 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Sale | 7,886 | 745.01 | 5,875,148 |
| 2022-11-04 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 727.82 | 727,820 |
| 2022-11-04 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 372.46 | 372,460 |
| 2022-11-04 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Option Ex | 34,000 | 381.92 | 12,985,280 |
| 2022-11-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 750.00 | 825,000 |
| 2022-11-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 372.46 | 409,706 |
| 2022-11-01 | Landry Robert E (EVP Finance CFO) | Sale | 482 | 757.89 | 365,305 |
| 2022-10-31 | Landry Robert E (EVP Finance CFO) | Option Ex | 2,000 | 381.92 | 763,840 |
| 2022-10-17 | Landry Robert E (EVP Finance CFO) | Sale | 358 | 739.50 | 264,741 |
| 2022-10-14 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,500 | 381.92 | 572,880 |
| 2022-10-05 | Fenimore Christopher R. (SVP Controller) | Sale | 1,844 | 749.00 | 1,381,156 |
| 2022-10-03 | Tessier-lavigne Marc (Director) | Sale | 3,612 | 718.00 | 2,593,416 |
| 2022-10-03 | Tessier-lavigne Marc (Director) | Option Ex | 3,612 | 413.33 | 1,492,947 |
| 2022-09-30 | Tessier-lavigne Marc (Director) | Sale | 3,428 | 698.00 | 2,392,744 |
| 2022-09-30 | Tessier-lavigne Marc (Director) | Option Ex | 3,428 | 413.33 | 1,416,895 |
| 2022-09-29 | Tessier-lavigne Marc (Director) | Sale | 3,798 | 694.51 | 2,637,764 |
| 2022-09-29 | Tessier-lavigne Marc (Director) | Option Ex | 3,798 | 413.33 | 1,569,827 |
| 2022-09-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 577.62 | 635,382 |
| 2022-09-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 342.93 | 377,223 |
| 2022-08-16 | Murphy Andrew J (EVP Research) | Sale | 3,513 | 644.61 | 2,264,525 |
| 2022-08-15 | Murphy Andrew J (EVP Research) | Option Ex | 10,000 | 179.13 | 1,791,300 |
| 2022-08-09 | Poon Christine A (Director) | Sale | 15,000 | 620.87 | 9,313,050 |
| 2022-08-09 | Poon Christine A (Director) | Option Ex | 15,000 | 177.82 | 2,667,300 |
| 2022-08-05 | Stahl Neil (EVP Research and Development) | Sale | 23,782 | 613.95 | 14,600,982 |
| 2022-08-04 | Stahl Neil (EVP Research and Development) | Option Ex | 95,000 | 270.43 | 25,690,850 |
| 2022-08-04 | Ryan Arthur F (Director) | Sale | 10,453 | 621.48 | 6,496,361 |
| 2022-08-04 | Ryan Arthur F (Director) | Option Ex | 10,453 | 412.58 | 4,312,730 |
| 2022-08-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 581.53 | 639,683 |
| 2022-08-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 342.93 | 377,223 |
| 2022-07-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 587.76 | 646,536 |
| 2022-07-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 342.93 | 377,223 |
| 2022-06-01 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 669.51 | 736,461 |
| 2022-06-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 342.93 | 377,223 |
| 2022-05-17 | Murphy Andrew J (EVP Research) | Sale | 3,543 | 663.17 | 2,349,629 |
| 2022-05-16 | Murphy Andrew J (EVP Research) | Option Ex | 10,000 | 179.13 | 1,791,300 |
| 2022-05-02 | Mccourt Marion (EVP Commercial) | Sale | 1,100 | 656.97 | 722,667 |
| 2022-05-02 | Mccourt Marion (EVP Commercial) | Option Ex | 1,100 | 342.93 | 377,223 |
| 2022-05-02 | Ryan Arthur F (Director) | Sale | 100 | 650.58 | 65,058 |
| 2022-04-11 | Landry Robert E (EVP Finance CFO) | Sale | 1,862 | 734.50 | 1,367,631 |
| 2022-04-08 | Fenimore Christopher R. (SVP Controller) | Option Ex | 7,450 | 413.05 | 3,077,222 |
| 2022-04-08 | Landry Robert E (EVP Finance CFO) | Sale | 325 | 736.48 | 239,355 |
| 2022-04-08 | Landry Robert E (EVP Finance CFO) | Option Ex | 8,000 | 390.79 | 3,126,320 |
| 2022-04-07 | Bassler Bonnie L (Director) | Sale | 1,240 | 725.00 | 899,000 |
| 2022-04-07 | Bassler Bonnie L (Director) | Option Ex | 1,240 | 380.95 | 472,378 |
| 2022-04-07 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,500 | 399.66 | 599,490 |
| 2022-04-07 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 5,114 | 721.10 | 3,687,705 |
| 2022-04-06 | Schleifer Leonard S (President & CEO) | Sale | 2,653 | 710.04 | 1,883,736 |
| 2022-04-05 | Schleifer Leonard S (President & CEO) | Sale | 4,461 | 710.05 | 3,167,533 |
| 2022-04-01 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 701.82 | 701,820 |
| 2022-04-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 342.93 | 342,930 |
| 2022-04-01 | Landry Robert E (EVP Finance CFO) | Sale | 316 | 698.74 | 220,801 |
| 2022-04-01 | Larosa Joseph J (EVP General Counsel and Secret) | Sale | 5,114 | 692.65 | 3,542,196 |
| 2022-04-01 | Ryan Arthur F (Director) | Sale | 100 | 693.17 | 69,316 |
| 2022-03-31 | Fenimore Christopher R. (SVP Controller) | Option Ex | 12,000 | 413.05 | 4,956,600 |
| 2022-03-31 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,500 | 399.66 | 599,490 |
| 2022-03-31 | Schleifer Leonard S (President & CEO) | Sale | 2,886 | 710.01 | 2,049,088 |
| 2022-03-30 | Bassler Bonnie L (Director) | Sale | 1,240 | 700.00 | 868,000 |
| 2022-03-30 | Bassler Bonnie L (Director) | Option Ex | 1,240 | 380.95 | 472,378 |
| 2022-03-30 | Goldstein Joseph L (Director) | Sale | 2,431 | 700.00 | 1,701,700 |
| 2022-03-30 | Goldstein Joseph L (Director) | Option Ex | 2,431 | 374.12 | 909,485 |
| 2022-03-30 | Brown Michael S (Director) | Sale | 408 | 699.00 | 285,192 |
| 2022-03-30 | Brown Michael S (Director) | Option Ex | 408 | 374.12 | 152,640 |
| 2022-03-30 | Vagelos P Roy (Director) | Sale | 28,572 | 700.01 | 20,000,685 |
| 2022-03-29 | Landry Robert E (EVP Finance CFO) | Sale | 2,683 | 688.04 | 1,846,008 |
| 2022-03-29 | Brown Michael S (Director) | Sale | 1,522 | 699.00 | 1,063,878 |
| 2022-03-29 | Brown Michael S (Director) | Option Ex | 1,522 | 374.12 | 569,410 |
| 2022-03-28 | Landry Robert E (EVP Finance CFO) | Option Ex | 14,500 | 462.06 | 6,699,928 |
| 2022-03-21 | Landry Robert E (EVP Finance CFO) | Sale | 300 | 693.00 | 207,900 |
| 2022-03-21 | Landry Robert E (EVP Finance CFO) | Option Ex | 400 | 381.92 | 152,768 |
| 2022-03-21 | Tessier-lavigne Marc (Director) | Sale | 7,439 | 690.00 | 5,132,910 |
| 2022-03-21 | Tessier-lavigne Marc (Director) | Option Ex | 7,439 | 380.95 | 2,833,887 |
| 2022-03-17 | Landry Robert E (EVP Finance CFO) | Sale | 83 | 686.00 | 56,938 |
| 2022-03-17 | Landry Robert E (EVP Finance CFO) | Option Ex | 365 | 381.92 | 139,400 |
| 2022-03-17 | Tessier-lavigne Marc (Director) | Sale | 7,830 | 680.00 | 5,324,400 |
| 2022-03-17 | Tessier-lavigne Marc (Director) | Option Ex | 7,830 | 376.69 | 2,949,482 |
| 2022-03-16 | Zoghbi Huda Y (Director) | Sale | 2,000 | 675.00 | 1,350,000 |
| 2022-03-16 | Zoghbi Huda Y (Director) | Option Ex | 2,000 | 391.92 | 783,840 |
| 2022-03-16 | Landry Robert E (EVP Finance CFO) | Sale | 300 | 677.00 | 203,100 |
| 2022-03-16 | Tessier-lavigne Marc (Director) | Sale | 4,361 | 675.00 | 2,943,675 |
| 2022-03-16 | Tessier-lavigne Marc (Director) | Option Ex | 4,361 | 374.12 | 1,631,537 |
| 2022-03-14 | Vagelos P Roy (Director) | Option Ex | 75,000 | 179.13 | 13,434,750 |
| 2022-03-01 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 615.39 | 615,390 |
| 2022-03-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 342.93 | 342,930 |
| 2022-03-01 | Ryan Arthur F (Director) | Sale | 100 | 615.47 | 61,547 |
| 2022-02-23 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Sale | 6,781 | 612.92 | 4,156,210 |
| 2022-02-23 | Brown Michael S (Director) | Sale | 500 | 608.68 | 304,340 |
| 2022-02-22 | Van Plew Daniel P (EVP & General Mgr, Industrial) | Option Ex | 40,000 | 399.66 | 15,986,400 |
| 2022-02-15 | Murphy Andrew J (EVP Research) | Sale | 3,540 | 629.34 | 2,227,856 |
| 2022-02-14 | Murphy Andrew J (EVP Research) | Option Ex | 10,000 | 179.13 | 1,791,300 |
| 2022-02-01 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 607.46 | 607,460 |
| 2022-02-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 342.93 | 342,930 |
| 2022-02-01 | Ryan Arthur F (Director) | Sale | 100 | 606.04 | 60,603 |
| 2022-01-03 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 625.00 | 625,000 |
| 2022-01-03 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 342.93 | 342,930 |
| 2022-01-03 | Ryan Arthur F (Director) | Sale | 100 | 625.07 | 62,506 |
| 2021-12-22 | Yancopoulos George (President and Chief Scientific) | Option Ex | 442,267 | 224.78 | 99,412,776 |
| 2021-12-13 | Mccourt Marion (EVP Commercial) | Sale | 344 | 653.12 | 224,673 |
| 2021-12-13 | Landry Robert E (EVP Finance CFO) | Sale | 116 | 662.50 | 76,850 |
| 2021-12-10 | Murphy Andrew J (EVP Research) | Sale | 7,122 | 664.97 | 4,735,894 |
| 2021-12-10 | Landry Robert E (EVP Finance CFO) | Sale | 781 | 664.66 | 519,102 |
| 2021-12-10 | Landry Robert E (EVP Finance CFO) | Option Ex | 1,500 | 555.67 | 833,504 |
| 2021-12-09 | Murphy Andrew J (EVP Research) | Option Ex | 16,500 | 52.03 | 858,495 |
| 2021-12-09 | Landry Robert E (EVP Finance CFO) | Option Ex | 4,250 | 399.66 | 1,698,555 |
| 2021-12-09 | Tessier-lavigne Marc (Director) | Sale | 3,784 | 665.00 | 2,516,360 |
| 2021-12-09 | Tessier-lavigne Marc (Director) | Option Ex | 3,784 | 371.40 | 1,405,377 |
| 2021-12-09 | Larosa Joseph J (EVP General Counsel and Secret) | Option Ex | 30,000 | 179.13 | 5,373,900 |
| 2021-12-03 | Stahl Neil (EVP Research and Development) | Option Ex | 72,500 | 179.13 | 12,986,925 |
| 2021-12-01 | Mccourt Marion (EVP Commercial) | Sale | 1,000 | 639.13 | 639,130 |
| 2021-12-01 | Mccourt Marion (EVP Commercial) | Option Ex | 1,000 | 342.93 | 342,930 |
| 2021-12-01 | Ryan Arthur F (Director) | Sale | 100 | 636.48 | 63,647 |
| 2021-11-22 | Sing George L (Director) | Sale | 2,000 | 657.50 | 1,315,000 |
| 2021-11-19 | Sing George L (Director) | Sale | 1,000 | 655.00 | 655,000 |
| 2021-11-19 | Schleifer Leonard S (President & CEO) | Option Ex | 520,313 | 224.78 | 116,955,956 |
| 2021-11-18 | Sing George L (Director) | Sale | 4,000 | 650.00 | 2,600,000 |
| 2021-11-17 | Landry Robert E (EVP Finance CFO) | Sale | 681 | 645.08 | 439,299 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.